清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management

乳腺癌 医学 亚太地区 肿瘤科 癌症 内科学 历史 民族学
作者
Winnie Yeo,Soo Chin Lee,Christian F. Singer,Judith Balmaña,Rebecca Dent,Veronique Kiak‐Mien Tan,Nadia Ayu Mulansari,Mastura Md Yusof,Frances Victoria Que,Yen‐Shen Lu,Napa Parinyanitikul,Cẩm Phương Phạm,Nur Aishah Mohd Taib,Sun‐Young Kong,Yoland Antill,Hee Jeong Kim
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:15
标识
DOI:10.3389/fonc.2025.1507840
摘要

Existing guidelines have practical gaps in decision and treatment sequencing for BRCA germline pathogenic variant breast cancers. This paper aims to develop clinical-practice consensus guidelines to address these gaps in the clinical management of BRCA germline pathogenic variants-associated breast cancer in the Asia-Pacific region. An expert panel of 16 medical oncologists, geneticists, and breast cancer surgeons from the Asia-Pacific region arrived at 25 statements. The high level of consensus of statements was considered at ≥75%. A survey of 134 healthcare practitioners, breast cancer surgeons, geneticists, oncologists, molecular biologists/pathologists explored the real- world practices in the Asia-Pacific region. A consensus was reached for 80% of the statements (20/25) and aligned with the international guidelines. A significant gap was observed between real-world practices and the recommendations of the steering committee members in discussing contralateral risk reducing mastectomy with the patients as a part of standard practice, considering poly ADP-ribose polymerase inhibitor (PARPi) + immunotherapy for early triple negative breast cancer (eTNBC) patients with BRCA variants who don't achieve pathological complete response after neoadjuvant chemotherapy + immunotherapy, use of adjuvant PARPi in patients with BRCA germline pathogenic variants in eTNBC who have achieved pathological complete response from neoadjuvant therapy, and preference for endocrine therapy + PARPi over endocrine therapy + cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as escalated adjuvant treatment for BRCA pathogenic variants with high-risk hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-negative) early breast cancer. Testing for BRCA germline pathogenic variants should be expanded to include all young patients with breast cancer. Patients with BRCA germline pathogenic variants should undergo genetic testing before surgery as it can impact surgical intervention decisions and further systemic treatment. The use of neoadjuvant platinum agents in chemotherapy increases the pathological complete response rate. Adjuvant PARPi is preferred over CDK4/6i as escalated treatment in patients who are HR+/HER2-negative.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dianeil发布了新的文献求助10
9秒前
19秒前
amiee发布了新的文献求助10
25秒前
somehgo的应助被betsydouglas14采纳,获得30
31秒前
共享精神的应助被ping采纳,获得10
33秒前
包容的初阳完成签到,获得积分10
39秒前
42秒前
激动的忆翠完成签到,获得积分10
47秒前
风趣馒头完成签到,获得积分10
55秒前
55秒前
无私的碧玉完成签到,获得积分10
58秒前
俭朴迎荷完成签到,获得积分10
59秒前
1分钟前
n01W97的应助被科研通管家采纳,获得70
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
怕黑靖荷完成签到,获得积分10
1分钟前
专一的思菱完成签到,获得积分10
1分钟前
1分钟前
欢呼亦绿完成签到,获得积分10
1分钟前
ping发布了新的文献求助10
1分钟前
文静飞松完成签到,获得积分10
2分钟前
喜悦的紫雪完成签到,获得积分10
2分钟前
故意的白风完成签到,获得积分10
2分钟前
要减肥的菀完成签到,获得积分10
3分钟前
矢思然完成签到,获得积分10
3分钟前
蓝意完成签到,获得积分0
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
cocolinfly完成签到 ,获得积分10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
Maestro_S的应助被科研通管家采纳,获得10
3分钟前
烂漫的诗蕊完成签到,获得积分10
3分钟前
快乐的如曼完成签到 ,获得积分10
3分钟前
淡淡傲柔完成签到,获得积分10
3分钟前
欣慰怀梦完成签到,获得积分10
4分钟前
漂亮忆曼完成签到,获得积分10
4分钟前
不如看海完成签到 ,获得积分10
4分钟前
Imran完成签到,获得积分10
4分钟前
霸气一斩完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834375
捐赠科研通 7782865
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481280